¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect


  • Factor de Impacto: 1,267(2015)
  • 5-años Factor de Impacto: 1,344
  • SCImago Journal Rank (SJR):0,22
  • Source Normalized Impact per Paper (SNIP):0,385
doi: 10.1016/S0025-7753(01)71793-9
Recomendaciones sobre la atención multidisciplinaria del paciente con glioma maligno
Francesc Grausa,, , Miguel Cerdáb, José Piquerc, Gaspar Reynésd, Manuel Santose
a Servicio de Neurología. Hospital Clínic. Universitat de Barcelona. Barcelona.
b Servicio de Anatomía Patológica. Hospital Clínico Universitario. Valencia.
c Servicio de Neurocirugía. Hospital de la Ribera. Alzira.
d Servicio de Oncología Médica. Hospital Universitario La Fe. Valencia.
e Servicio de Oncología Radioterapia. M.D. Anderson. Madrid.
Palabras clave
Glioma maligno, Glioblastoma, Astrocitoma
El Texto completo solo está disponible en PDF
Referencias Bibliográficas
T.S. Surawicz,B.J. McCarthy,V. Kupelian,P.J. Jukich,J.M. Bruner,F.G. Davis
Descriptive epidemiology of primary CNS tumors: results from the central brain tumor registry of the Unitades States 1990-1994
NeuroOncology, 1 (1999), pp. 14-25
J.E. Riggs
Rising primary malignant brain tumor mortality in the elderly
Arch Neurol, 52 (1995), pp. 571-575
C.h.J. Vecht,A. Hovestadt,H.B.C. Verbiest,J.J. Van Vliet,W.L.J. Van Putten
Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors. A randomized study of doses of 4, 8, and 16 mg per day
Neurology, 44 (1994), pp. 675-680
M.J. Glantz,B.F. Cole,P.A. Forsyth,L. Recht,P.Y. Wen,M.C. Chamberlain
Practice parameter: anticonvulsivant prophylaxis in patients with newly diagnosed brain tumors
Neurology, 54 (2000), pp. 1886-1893
S.A. Grossman,V.R. Sheidler,M.R. Gilbert
Decreased phenytoin levels in patients receiving chemotherapy
Am J Med, 87 (1989), pp. 505-510
L.C. Marras,W.H. Geerts,J.R. Perry
The risk of venous thromboembolism is increased throughout the course of malignant glioma
Cancer, 89 (2000), pp. 640-646
K.R. Hess
Extent of resection as a prognostic variable in the treatment of gliomas
J Neuro Oncol, 42 (1999), pp. 227-231
C. Fadul,J. Wood,H. Thaler,J. Galicich,R.H. Patterson,J.B. Posner
Morbility and mortality of craniotomy for excision of supratentorial gliomas
Neurology, 38 (1988), pp. 1374-1379
J.W. Kernohan,R.F. Maybon,H.J. Svien,A.W. Adson
A simplified classification of the gliomas
Proc Staff Meet Mayo Clin, 24 (1949), pp. 71-75
P. Kleihues,P.C. Burger,B.W. Scheithauer
Histological typing of tumors of the central nervous system
International histological classification of tumors,
P.C. Burger,F.S. Vogel,S.B. Green,T.A. Strike
Glioblastoma multiforme and anaplastic astrocytoma: pathological criteria and prognostic implications
Cancer, 56 (1985), pp. 1106-1111
C. Daumas-Duport,B. Scheithauer,J. O´Fallon,P. Kelly
Grading of astrocytomas. A simple and reproducible method
Cancer, 62 (1988), pp. 2152-2165
S.W. Coons,P.C. Johnson,B.W. Scheithauer,A.J. Yates,D.K. Pearl
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
Cancer, 79 (1997), pp. 1381-1393
W.J. Curran,C.h.B. Scott,J. Horton,J.S. Nelson,A.S. Weinstein,J. Fischbach
Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
J Natl Cancer Inst, 85 (1993), pp. 704-710
M. Werner-Wasik,C.B. Scott,D.F. Nelson,L.E. Gaspar,K.J. Murray,J.A. Fischbach
Final report of a phase I/II trial of hyperfractonated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02
Cancer, 77 (1996), pp. 1535-1543
M. Brada,G. Sharpe,B. Rajan,J. Britton,P.R. Wilkins,D. Guerrero
Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration
J Radiat Oncol Biol Phys, 43 (1999), pp. 287-292
R.G. Selker,M.S. Eddy,M. Deutsch,V.C. Arena,P. Burger
On the development on an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate 125I implants in “failed” and “newly diagnosed” glioblastoma patients: quality assurance methodology and a possible future adjuvant therapeutic enhancement
J Neurooncol, 26 (1995), pp. 141-155
N.J. Laperriere,P.M. Leung,S. McKenzie,M. Milosevic,S. Wong,J. Glen
Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma
Int J Radiat Oncol Biol Phys, 41 (1998), pp. 1005-1011
D.C. Shrieve,E. Alexander III,P.Mc.L. Black,P.Y. Wen,H.A. Fine,H.M. Kooy
Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long term outcome
J Neurosurg, 90 (1999), pp. 72-77
S.F. Shepherd,R.W. Laing,V.P. Cosgrove,A.P. Warrington,F. Hines,S.E. Ashley
Hypofractionated stereotactic radiotherapy in the management of recurrent glioma
Int J Radiat Oncol Biol Phys, 37 (1997), pp. 393-398
K. Nakagawa,Y. Aoki,T. Fujimaki,M. Tago,A. Terahara,K. Karasawa
High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme
Int J Radiat Oncol Biol Phys, 40 (1998), pp. 1141-1149
A.D. Chanana,J. Capala,M. Chadna,J.A. Coderre,A.Z. Diaz,E.H. Elowitz
Boron neutron capture therapy for glioblastoma multiforme: Interim results from the phase I/II dose-escalation studies
Neurosurgery, 44 (1999), pp. 1182-1193
J.G. Caincross,K. Ueki,M. Zlatescu,D.K. Lisle,D.M. Finkelstein,R.R. Hammond
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. current treatment of oligodendrogliomas
J Natl Cancer Inst, 90 (1998), pp. 1473-1479
J.G. Caincross,D. MacDonald,S. Ludwin,D. Lee,T. Cascino,J. Buckner
Chemotherapy for anaplastic oligodendroglioma
J Clin Oncol, 12 (1994), pp. 2013-2021
V.A. Levin,P. Silver,J. Hannigan,W.M. Wara,P.H. Gutin,R.L. Davis
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 Final report
Int J Radiat Oncol Biol Phys, 18 (1990), pp. 314-324
J. Hildebrand,T. Sahmoud,F. Mignolet,J.M. Brucher,D. Afray el
EORTC Brain Tumor Group. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas
Neurology, 44 (1994), pp. 1479-1483
W.K.A. Yung,M.D. Prados,R. Yaya-Tur,S.S. Rosenfeld,M. Brada,H.S. Friedman
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
J Clin Oncol, 17 (1999), pp. 2762-2771
H. Fine,K.B.G. Dear,J.S. Loefler,P.M. Black,G.P. Canellos
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
Cancer, 71 (1993), pp. 2585-2597
W.A. Hall,H.R. Djalilian,P.W. Sperduto,K.H. Cho,B.J. Gerbi,J.P. Gibbons
Stereotactic radiosurgery for recurrent malignant gliomas
J Clin Oncol, 13 (1995), pp. 1642-1648
P.A.J. Forsyth,E. Petrov,H. Mahallati,J.G. Cairncross,P. Brasher,M.E. MacRae
Prospective study of postoperative magnetic resonance imaging in patients with malignant glioma
J Clin Oncol, 15 (1997), pp. 2076-2081
M. Forsting,F.K. Albert,S. Kunze,H.P. Adams,D. Zenner,K. Sartor
Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns
AJNR, 14 (1993), pp. 77-87
D.R. Macdonald,T.L. Cascino,S.C. Schold,J.G. Cairncross
Response criteria for phase II studies of supratentorial malignant glioma
J Clin Oncol, 8 (1990), pp. 1277-1280
Correspondencia: Dr. F. Graus. Servei de Neurologia. Hospital Clínic. Villarroel, 170. 08036 Barcelona.
Copyright © 2001. Elsevier España, S.L.